7/9/2024

Belimumab Injection

Reason for the Shortage

- GSK did not provide a reason for the shortage.

Available Products

- Benlysta subcutaneous injection, GSK, 200 mg/mL, 1 mL auto-injector, 1 count, NDC 49401-0088-35
- Benlysta subcutaneous injection, GSK, 200 mg/mL, 1 mL syringe, 1 count, NDC 49401-0088-47
- Benlysta injection, GSK, 120 mg, vial, 1 count, NDC 49401-0101-01
- Benlysta injection, GSK, 400 mg, vial, 1 count, NDC 49401-0102-01

Estimated Resupply Dates

- GSK has Benlysta 120 mg and 400 mg vials available. The 200 mg/mL 1 mL auto-injectors and syringes are available.

Implications for Patient Care

- Transition pediatric patients to alternative agents.
- Start patients on subcutaneous therapy when possible.
- Systemic lupus erythematosus (SLE) - Per package labeling, to transition to subcutaneous dosing from intravenous dosing, administer first subcutaneous dose 1 to 4 weeks after the last IV dose (200 mg once weekly).
- Active Lupus Nephritis - Per package labeling, to transition to subcutaneous dosing from intravenous dosing, you may transition after 2 x IV doses. Administer first subcutaneous dose 1 to 2 weeks after the last IV dose (200 mg once weekly)

Updated

Updated July 9, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created December 14, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.